Literature DB >> 16648655

Relationship of Helicobacter pylori to Bcl-2 family expression, DNA content, and pathological characteristics of gastric cancer.

Mohamed El-Shahat1, Samir El-Masry, Mahmoud Lotfy, Ayman El-Meghawry El-Kenawy, Wesam A Nasif.   

Abstract

BACKGROUND: Despite the fact that the association of Helicobacter pylori with an increased risk of gastric cancer has been well documented, the exact mechanisms of this association have not been fully elucidated. Scarce data on H. pylori infection and its relationship with the different pathological characteristics are available in Egypt. AIM OF THE STUDY: The rationale of the present study was to determine the prevalence of H. pylori in a group of gastric cancer patients and to analyze the relationship between H. pylori infection with the different pathological characteristics including the types of gastric cancer and tumor location within the stomach, in addition, to investigate the Bcl-2 and Bax expressions along with DNA flow cytometric analysis in the gastric cancer patients with and without H. pylori infection.
METHODS: Samples were obtained from 66 consecutive patients with gastric cancer (46 males and 20 females). The youngest patient was 20 yr old, the oldest 76 yr with mean age of 52.8 yr. The samples were subjected for histopathological characterization, H. pylori detection, DNA flow cytometric analysis, and Bcl-2 and Bax expressions detection, in addition to apoptosis analysis.
RESULTS: The obtained results showed that the H. pylori infection was found in 38/66 (57.6%) [Odds ratio=1.357 with 95% confidence interval (CI) 0.84-2.2]. There was a statistical significance for Bcl-2, Bax, and apoptosis with H. pylori status (p = 0.009, 0.008, 0.032, respectively). On the other hand, There was a statistical significance for H. pylori infection with the disease grade (p = 0.015) and lymph node metastasis (p = 0.05). No statistical significance was found between H. pylori status with the patients' age, gender, tumor site, tumor type, depth of invasion, and stromal reaction.
CONCLUSIONS: These data may indicate that the H. pylori infection not only contributes in the disease formation through the apoptosis dysregulation but also takes a part in the disease dissemination and progression. In addition, it may reflect a biologic, pathogenic, and ethnic background affecting the relationship of H. pylori infection to gastric cancer in the Egyptian patients. A high rate of smoking in Egypt and the diet are important factors that may affect such background. Further studies are warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16648655     DOI: 10.1385/ijgc:36:2:61

Source DB:  PubMed          Journal:  Int J Gastrointest Cancer        ISSN: 1537-3649


  42 in total

1.  Flow cytometric analysis of the DNA content in primary and metastatic lesions of colorectal cancer.

Authors:  H Tomoda; T Inoue
Journal:  J Surg Oncol       Date:  1995-06       Impact factor: 3.454

2.  Expression of matrix metalloprotease-2, -7 and -9 on human colon, liver and bile duct cell lines by enteric and gastric Helicobacter species.

Authors:  Naoko Yanagisawa; Linda Geironson; Waleed Abu Al-Soud; Sa Ljungh
Journal:  FEMS Immunol Med Microbiol       Date:  2005-05-01

3.  Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons.

Authors:  C P Dooley; H Cohen; P L Fitzgibbons; M Bauer; M D Appleman; G I Perez-Perez; M J Blaser
Journal:  N Engl J Med       Date:  1989-12-07       Impact factor: 91.245

4.  Virulence and potential pathogenicity of coccoid Helicobacter pylori induced by antibiotics.

Authors:  F F She; D H Su; J Y Lin; L Y Zhou
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

Review 5.  Recent developments in Helicobacter pylori vaccination.

Authors:  J G Kusters
Journal:  Scand J Gastroenterol Suppl       Date:  2001

Review 6.  Matrilysin (matrix metalloproteinase-7): a new promising drug target in cancer and inflammation?

Authors:  Ben Wielockx; Claude Libert; Carole Wilson
Journal:  Cytokine Growth Factor Rev       Date:  2004 Apr-Jun       Impact factor: 7.638

7.  Flow-cytometric DNA content analysis of oesophageal carcinoma. Comparison between tumour and sequential non-tumour mucosae.

Authors:  L S Wang; L H Wu; C J Chang; W Y Li; H J Fahn; M H Huang; J H Chiu
Journal:  Scand Cardiovasc J       Date:  1998       Impact factor: 1.589

8.  Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population.

Authors:  M Asaka; T Kimura; M Kudo; H Takeda; S Mitani; T Miyazaki; K Miki; D Y Graham
Journal:  Gastroenterology       Date:  1992-03       Impact factor: 22.682

9.  Effect of Helicobacter pylori on apoptosis and apoptosis related genes in gastric cancer cells.

Authors:  Y Yang; C S Deng; J Z Peng; B C-Y Wong; S K Lam; H H-X Xia
Journal:  Mol Pathol       Date:  2003-02

10.  Helicobacter pylori infection in gastric carcinoma.

Authors:  T Kato; Y Saito; M Niwa; H Inoue; N Motoyama; K Ogoshi; A Nashimoto; J Sasaki; T Sato; M Asaka
Journal:  Eur J Gastroenterol Hepatol       Date:  1994-12       Impact factor: 2.566

View more
  3 in total

Review 1.  Horizontal gene transfers with or without cell fusions in all categories of the living matter.

Authors:  Joseph G Sinkovics
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

2.  Effects of a Potential Probiotic Strain Lactobacillus gasseri ATCC 33323 on Helicobacter pylori-Induced Inflammatory Response and Gene Expression in Coinfected Gastric Epithelial Cells.

Authors:  Mahdieh Yarmohammadi; Abbas Yadegar; Maryam Tajabadi Ebrahimi; Mohammad Reza Zali
Journal:  Probiotics Antimicrob Proteins       Date:  2020-11-18       Impact factor: 4.609

3.  Dangerous Liaison: Helicobacter pylori, Ganglionitis, and Myenteric Gastric Neurons: A Histopathological Study.

Authors:  Liana Sticlaru; Florica Stăniceanu; Mirela Cioplea; Luciana Nichita; Alexandra Bastian; Gianina Micu; Cristiana Popp
Journal:  Anal Cell Pathol (Amst)       Date:  2019-12-30       Impact factor: 2.916

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.